Tribolium castaneum defensin 1 kills Moraxella catarrhalis in an in vitro infection model but does not harm commensal bacteria

Bertrams, Wilhelm; Lindhauer, Nora S.; Rieke, Marie Christin; Paas, Anne; Hoffmann, Kerstin; Greene, Brandon; Visekruna, Alexander; Vilcinskas, Andreas; Seidel, Kerstin; Schmeck, Bernd

doi:10.1080/21505594.2021.1908741

Cited by 8 publications

(2 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We studied the impact of AMP #5 treatment on the macrophage response to infection with Streptococcus pneumoniae ( Fig. 5a ) 30,31 . AMP #5 resulted in only low cytotoxic damage ( Fig.…”

Section: Resultsmentioning

confidence: 99%

Cell-free biosynthesis combined with deep learning accelerates de novo-development of antimicrobial peptides

Pandi

Adam

Zare

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

Bioactive peptides are key molecules in health and medicine. Deep learning holds a big promise for the discovery and design of bioactive peptides. Yet, suitable experimental approaches are required to validate candidates in high throughput and at low cost. Here, we established a cell-free protein synthesis (CFPS) pipeline for the rapid and inexpensive production of antimicrobial peptides (AMPs) directly from DNA templates. To validate our platform, we used deep learning to design thousands of AMPs de novo. Using computational methods, we prioritized 500 candidates that we produced and screened with our CFPS pipeline. We identified 30 functional AMPs, which we characterized further through molecular dynamics simulations, antimicrobial activity and toxicity. Notably, six de novo-AMPs feature broad-spectrum activity against multidrug-resistant pathogens and do not develop bacterial resistance. Our work demonstrates the potential of CFPS for production and testing of bioactive peptides within less than 24 hours and <10$ per screen.

show abstract

“…We studied the impact of AMP #5 treatment on the macrophage response to infection with Streptococcus pneumoniae ( Fig. 5a ) 30,31 . AMP #5 resulted in only low cytotoxic damage ( Fig.…”

Section: Resultsmentioning

confidence: 99%

Cell-free biosynthesis combined with deep learning accelerates de novo-development of antimicrobial peptides

Pandi

Adam

Zare

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, NF-κB activation is blocked by peptide A [ 52 ]. Defensin 1 from the red flour beetle Tribolium castaneum decreases production and release of IL-1β, IL-6, IL-8, IL-10, IL-12p70, IL-23, and TNF-α in blood-derived macrophages [ 53 ]. CopA5 is composed of five amino acids (LLCIA) from the CopA3 peptide (LLCIALRKK, D-form) originally isolated from the Korean dung beetle.…”

Section: Regulatory Effect Of Amps On Macrophagesmentioning

confidence: 99%

The Contribution of Antimicrobial Peptides to Immune Cell Function: A Review of Recent Advances

Li,

Niu,

Wang

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

The development of novel antimicrobial agents to replace antibiotics has become urgent due to the emergence of multidrug-resistant microorganisms. Antimicrobial peptides (AMPs), widely distributed in all kingdoms of life, present strong antimicrobial activity against a variety of bacteria, fungi, parasites, and viruses. The potential of AMPs as new alternatives to antibiotics has gradually attracted considerable interest. In addition, AMPs exhibit strong anticancer potential as well as anti-inflammatory and immunomodulatory activity. Many studies have provided evidence that AMPs can recruit and activate immune cells, controlling inflammation. This review highlights the scientific literature focusing on evidence for the anti-inflammatory mechanisms of different AMPs in immune cells, including macrophages, monocytes, lymphocytes, mast cells, dendritic cells, neutrophils, and eosinophils. A variety of immunomodulatory characteristics, including the abilities to activate and differentiate immune cells, change the content and expression of inflammatory mediators, and regulate specific cellular functions and inflammation-related signaling pathways, are summarized and discussed in detail. This comprehensive review contributes to a better understanding of the role of AMPs in the regulation of the immune system and provides a reference for the use of AMPs as novel anti-inflammatory drugs for the treatment of various inflammatory diseases.

show abstract

Combating Escherichia coli O157:H7 with Functionalized Chickpea‐Derived Antimicrobial Peptides

Yang

Zou

et al. 2022

Advanced Science

View full text Add to dashboard Cite

The rapid dissemination of antibiotic resistance accelerates the desire for new antibacterial agents. Here, a class of antimicrobial peptides (AMPs) is designed by modifying the structural parameters of a natural chickpea-derived AMP-Leg2, termed "functionalized chickpea-derived Leg2 antimicrobial peptides" (FCLAPs). Among the FCLAPs, KTA and KTR show superior antibacterial efficacy against the foodborne pathogen Escherichia coli (E. coli) O157:H7 (with MICs in the range of 2.5-4.7 μmol L −1 ) and demonstrate satisfactory feasibility in alleviating E. coli O157:H7-induced intestinal infection. Additionally, the low cytotoxicity along with insusceptibility to antimicrobial resistance increases the potential of FCLAPs as appealing antimicrobials. Combining the multi-omics profiling andpeptide-membrane interaction assays, a unique dual-targeting mode of action is characterized. To specify the antibacterial mechanism, microscopical observations, membrane-related physicochemical properties studies, and mass spectrometry assays are further performed. Data indicate that KTA and KTR induce membrane damage by initially targeting the lipopolysaccharide (LPS), thus promoting the peptides to traverse the outer membrane. Subsequently, the peptides intercalate into the peptidoglycan (PGN) layer, blocking its synthesis, and causing a collapse of membrane structure. These findings altogether imply the great potential of KTA and KTR as promising antibacterial candidates in combating the growing threat of E. coli O157:H7.

show abstract

Tribolium castaneum defensin 1 kills Moraxella catarrhalis in an in vitro infection model but does not harm commensal bacteria

Cited by 8 publications

References 28 publications

Cell-free biosynthesis combined with deep learning accelerates de novo-development of antimicrobial peptides

Cell-free biosynthesis combined with deep learning accelerates de novo-development of antimicrobial peptides

The Contribution of Antimicrobial Peptides to Immune Cell Function: A Review of Recent Advances

Combating Escherichia coli O157:H7 with Functionalized Chickpea‐Derived Antimicrobial Peptides

Contact Info

Product

Resources

About